Cargando…

BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation

EGFR TKI therapy has become a first-line regimen for non-small cell lung cancer (NSCLC) patients with EGRF mutations. However, there are two big challenges against effective therapy--the secondary EGFR mutation-associated TKI resistance and brain metastasis (BMs) of lung cancer. The BMs is a major c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Weimin, Zhao, Yuge, Kang, Xuejia, Zhao, Pengfei, Fu, Xuhong, Mo, Xiaopeng, Wan, Yakun, Huang, Yongzhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255027/ https://www.ncbi.nlm.nih.gov/pubmed/32483443 http://dx.doi.org/10.7150/thno.42234

Ejemplares similares

Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery
por: Zheng, Zening, et al.
Publicado: (2020)

Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy
por: Zhao, Ting, et al.
Publicado: (2022)

NAG-PEGylated multilamellar liposomes for BBB-GLUT transporter targeting
por: Kamal, Nahid S., et al.
Publicado: (2019)

Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer
por: Wang, Yuanyuan, et al.
Publicado: (2019)

Codelivery of Chemotherapeutics via Crosslinked Multilamellar Liposomal Vesicles to Overcome Multidrug Resistance in Tumor
por: Liu, Yarong, et al.
Publicado: (2014)

Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity
por: Liu, Yarong, et al.
Publicado: (2014)

Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi, Ye, et al.
Publicado: (2018)

Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
por: Rauca, Valentin-Florian, et al.
Publicado: (2021)

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
por: Zhang, Yue, et al.
Publicado: (2017)

Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB)
por: Sela, Hagit, et al.
Publicado: (2015)

Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size
por: Faresjö, Rebecca, et al.
Publicado: (2021)

Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects
por: Jiang, Hong, et al.
Publicado: (2019)

Effect of Chitosan and Liposome Nanoparticles as Adjuvant Codelivery on the Immunoglobulin G Subclass Distribution in a Mouse Model
por: Haryono, Agus, et al.
Publicado: (2017)

Dual-Functional Peptide Driven Liposome Codelivery System for Efficient Treatment of Doxorubicin-Resistant Breast Cancer
por: Ahmed, Kamel S, et al.
Publicado: (2021)

Surface PEGylated Cancer Cell Membrane-Coated Nanoparticles for Codelivery of Curcumin and Doxorubicin for the Treatment of Multidrug Resistant Esophageal Carcinoma
por: Gao, Yi, et al.
Publicado: (2021)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko, Brian, et al.
Publicado: (2017)

BBB building
por: Robinson, Richard
Publicado: (2008)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
por: Wei, Bing, et al.
Publicado: (2019)

The synergistic effect of chlorotoxin-mApoE in boosting drug-loaded liposomes across the BBB
por: Formicola, Beatrice, et al.
Publicado: (2019)

Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer
por: Li, Longxia, et al.
Publicado: (2022)

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations
por: Zang, Shu-Zhi, et al.
Publicado: (2017)

Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA
por: Zhang, Rui, et al.
Publicado: (2018)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

Codelivery of a cytotoxin and photosensitiser via a liposomal nanocarrier: a novel strategy for light-triggered cytosolic release
por: Yaghini, Elnaz, et al.
Publicado: (2018)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
por: Yamada, Teppei, et al.
Publicado: (2013)

Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy
por: Zhao, Pengfei, et al.
Publicado: (2018)

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
por: Xiang, Mingli, et al.
Publicado: (2013)

Structural insights into drug development strategy targeting EGFR T790M/C797S
por: Zhu, Su-Jie, et al.
Publicado: (2018)

Fabrication and Characterization of Paclitaxel and Resveratrol Loaded Soluplus Polymeric Nanoparticles for Improved BBB Penetration for Glioma Management
por: Hussain, Talib, et al.
Publicado: (2021)

Codelivery of Anticancer Drug and Photosensitizer by PEGylated Graphene Oxide and Cell Penetrating Peptide Enhanced Tumor-Suppressing Effect on Osteosarcoma
por: Zhang, Yi-Fei, et al.
Publicado: (2021)

A Dual Receptor Targeting- and BBB Penetrating- Peptide Functionalized Polyethyleneimine Nanocomplex for Secretory Endostatin Gene Delivery to Malignant Glioma
por: Lu, Lu, et al.
Publicado: (2020)

Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona
por: He, Yang, et al.
Publicado: (2022)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019)

Improved Antiglioblastoma Activity and BBB Permeability by Conjugation of Paclitaxel to a Cell‐Penetrative MMP‐2‐Cleavable Peptide
por: Hua, Dan, et al.
Publicado: (2020)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

When the BBB goes MIA
por: Pearson, Caroline A., et al.
Publicado: (2022)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
por: Matsuda, Asako, et al.
Publicado: (2019)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cjbfu2jm7dc6trqnvu1hdmjj38